Moreover, recent non-invasive imaging techniques using Aβ- and tau-PET tracers have led to the preclinical diagnosis of AD, allowing its evolution during the patient’s lifetime to be tracked [5,6,7]. This evidence concerns the gene MAPT and Alzheimer disease.